RenovoRx announces common stock offering, no amount given

RenovoRx (RNXT) announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of common stock. All of the securities to be sold in the proposed offering will be offered by RenovoRx. RenovoRx intends to use the net proceeds received from the offering for working capital and general corporate purposes, including continued progression of its Phase III TIGeR-PaC study and the continued development and execution of commercial sales and marketing activities for RenovoCath as a standalone device. Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering.